|
Adenocarcinoma of large intestine
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Hyperalgesia
|
0.240 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> Low GRK2 in nociceptors is critical to develop a primed state in response to GDNF and leads to engagement of Epac signaling and transition to chronic PGE<sub>2</sub>-induced hyperalgesia.
|
29922165 |
2018 |
|
Liver carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> The present study was designed to investigate the role of activated β2-AR in M2-polarized macrophages in the HCC progression and GRK2 regulatory effect, as well as the underlying mechanisms involved.
|
31371988 |
2019 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
RGD |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Congestive heart failure
|
0.600 |
Therapeutic
|
disease |
RGD |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Congestive heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
(-)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure.
|
29247373 |
2018 |
|
Hypertensive left ventricular hypertrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hypertensive left ventricular hypertrophy: relation to beta-adrenergic receptor kinase-1 (betaARK1) in peripheral lymphocytes.
|
15097244 |
2004 |
|
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
GRK2 may play a role in hyperphosphorylation of tau in tauopathies.
|
17146290 |
2006 |
|
Obesity
|
0.080 |
Biomarker
|
disease |
BEFREE |
G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity.
|
20627936 |
2010 |
|
Coronary Arteriosclerosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.
|
21518983 |
2011 |
|
Myocardial Ischemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.
|
21518983 |
2011 |
|
Right Ventricular Hypertrophy
|
0.210 |
Biomarker
|
disease |
RGD |
GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension.
|
23124027 |
2012 |
|
Right Ventricular Hypertrophy
|
0.210 |
Biomarker
|
disease |
BEFREE |
GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension.
|
23124027 |
2012 |
|
Hypertensive disease
|
0.550 |
Biomarker
|
group |
BEFREE |
GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension.
|
23124027 |
2012 |
|
Harlequin Fetus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GRK2 expression and membrane translocation were up-regulated under HG/HI conditions.
|
24570070 |
2014 |
|
Metabolic Syndrome X
|
0.010 |
Biomarker
|
disease |
BEFREE |
GRK2 abundance is increased in humans with metabolic syndrome and in different murine models of insulin resistance.
|
26198359 |
2015 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
G protein-coupled receptor kinase 2 (GRK2) is a serine/threonine kinase that is involved in a variety of important signaling pathways and alternation of GRK2 protein level or activity causes diseases such as heart failure, rheumatoid arthritis, and obesity.
|
26936374 |
2016 |
|
Congestive heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
G protein-coupled receptor kinase 2 (GRK2) is a serine/threonine kinase that is involved in a variety of important signaling pathways and alternation of GRK2 protein level or activity causes diseases such as heart failure, rheumatoid arthritis, and obesity.
|
26936374 |
2016 |
|
Obesity
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
G protein-coupled receptor kinase 2 (GRK2) is a serine/threonine kinase that is involved in a variety of important signaling pathways and alternation of GRK2 protein level or activity causes diseases such as heart failure, rheumatoid arthritis, and obesity.
|
26936374 |
2016 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GRK2 is up-regulated in breast cancer cell lines, in spontaneous tumors in mice, and in a proportion of invasive ductal carcinoma patients.
|
27720394 |
2016 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GRK2 is up-regulated in breast cancer cell lines, in spontaneous tumors in mice, and in a proportion of invasive ductal carcinoma patients.
|
27720394 |
2016 |
|
Invasive Ductal Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
GRK2 is up-regulated in breast cancer cell lines, in spontaneous tumors in mice, and in a proportion of invasive ductal carcinoma patients.
|
27720394 |
2016 |
|
Cardiovascular Diseases
|
0.340 |
Biomarker
|
group |
BEFREE |
GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease.
|
28077324 |
2018 |
|
physical symptom
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
βARK1 was significantly associated with HFSPS scores (β = 0.22 ± 0.10, p = 0.038), adjusting for other predictors of physical symptoms (model R<sup>2</sup> = 0.250, F(7, 70) = 3.34, p = 0.004).
|
29803296 |
2019 |